Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching Sildenafil to Riociguat in CTEPH After BPA (S2R)
NCT06715280Phase 4Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by The Chinese University of Hong Kong. Started Jul 2024; status: recruiting.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT06715280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715280.